Reviewed by Michael Gill, B. Sc.
6 SJIA Clinical Trials Near Me
Top Hospitals for SJIA Clinical Trials
Image of Cincinnati Children's Hospital Medical Center in Ohio.
Cincinnati Children's Hospital Medical Center
Cincinnati
3Active Trials
9All Time Trials for SJIA
1994First SJIA Trial
Image of Childrens Hospital Los Angeles in California.
Childrens Hospital Los Angeles
Los Angeles
2Active Trials
2All Time Trials for SJIA
2022First SJIA Trial
Top Cities for SJIA Clinical Trials
Image of Cincinnati in Ohio.
Cincinnati
5Active Trials
Cincinnati Children's Hospital Medical CenterTop Active Site
SJIA Clinical Trials by Phase of Trial
Phase 1 SJIA Clinical Trials
2Active SJIA Clinical Trials
2Number of Unique Treatments
18Number of Active Locations
SJIA Clinical Trials by Age Group
Top Treatments for SJIA Clinical Trials
Treatment Name
Active SJIA Clinical Trials
All Time Trials for SJIA
First Recorded SJIA Trial
Ustekinumab
2
2
2022
Emapalumab
1
1
2018
AEVI-007 (CERC-007, AVTX-007)
1
1
2021
In open-label phase: treatment with tofacitinib
1
1
2018
Golimumab
1
2
2010

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: November 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Leu JH, Shiff NJ, Clark M, Bensley K, Lomax KG, Berezny K, Nelson RM, Zhou H, Xu Z. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Paediatr Drugs. 2022 Sep 28. doi: 10.1007/s40272-022-00533-y. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/361715152 Leu JH, Shiff NJ, Clark M, Bensley K, Lomax KG, Berezny K, Nelson RM, Zhou H, Xu Z. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Paediatr Drugs. 2022 Nov;24(6):699-714. doi: 10.1007/s40272-022-00533-y. Epub 2022 Sep 28. https://pubmed.ncbi.nlm.nih.gov/361715153 Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO) . Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 2;60(10):4495-4507. doi: 10.1093/rheumatology/keab021. https://pubmed.ncbi.nlm.nih.gov/334933124 Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 2;60(10):4495-4507. doi: 10.1093/rheumatology/keab021. https://pubmed.ncbi.nlm.nih.gov/334933125 Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Open-Label Phase 3 Study of Intravenous Golimumab in Patients With Polyarticular Juvenile Idiopathic Arthritis. Rheumatology (Oxford). 2021 Jan 25. pii: keab021. doi: 10.1093/rheumatology/keab021. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/33493312